Objective: To assess the added value of maternal serum levels of IL-6 in women with preterm-prelabor rupture of membranes (PPROM) as a non-invasive test for the prediction of histological chorioamnionitis (HCA). Methods: This was a prospective cohort study of pregnant women between 20 + 0 and 36 + 6 weeks of gestation with a confirmed diagnosis of PPROM. Logistic regression models were created for the prediction of HCA and compared by assessing the improvement in their Naegelkerke R2 as a measure of goodness of fit. Predictive performance of all models was assessed by receiver operating characteristics curve (ROC) analysis and compared by the DeLong method. Results: From 47 women with PPROM, 31 (66%) developed HCA. Maternal serum IL-6 ≥19.5 pg/dL was the best cut-off point for the prediction of HCA (OR = 15; 95% CI: 3.6–61; p < 0.01). A model comprising maternal characteristics and IL-6 ≥19.5 pg/dL showed an area under the curve of 0.85 (95% CI: 0.74–0.95), significantly improving the previous models of IL-6 ≥19.5 pg/dL (R2: 23.3 vs. 34.1%; p = 0.01) or maternal characteristics (R2: 8.4 vs. 34.1%; p < 0.01). Conclusions: A model comprising maternal serum levels of IL-6 plus maternal characteristics proves to be a good non-invasive predictor of HCA.

Keywords:
Preterm delivery, Preterm rupture of membranes, Chorioamnionitis, Interleukin-6, Cytokines, Neonatal outcome
1.
Cobo T, Kacerovsky M, Palacio M, Hornychova H, Hougaard DM, Skogstrand K, Jacobsson B: Intra-amniotic inflammatory response in subgroups of women with preterm prelabor rupture of the membranes. PLoS One 2012; 7:e43677.
2.
Elimian A, Verma U, Beneck D, Cipriano R, Visintainer P, Tejani N: Histologic chorioamnionitis, antenatal steroids, and perinatal outcomes. Obstet Gynecol 2000; 96: 333–336.
3.
Kim SA, Park KH, Lee SM: Non-invasive prediction of histologic chorioamnionitis in women with preterm premature rupture of membranes. Yonsei Med J 2016; 57: 461–468.
4.
Been JV, Rours IG, Kornelisse RF, Lima Passos V, Kramer BW, Schneider TA, de Krijger RR, Zimmermann LJ: Histologic chorioamnionitis, fetal involvement, and antenatal steroids: effects on neonatal outcome in preterm infants. Am J Obstet Gynecol 2009; 201: 587 e581–e588.
5.
Soraisham AS, Trevenen C, Wood S, Singhal N, Sauve R: Histological chorioamnionitis and neurodevelopmental outcome in preterm infants. J Perinatol 2013; 33: 70–75.
6.
Suppiej A, Franzoi M, Vedovato S, Marucco A, Chiarelli S, Zanardo V: Neurodevelopmental outcome in preterm histological chorioamnionitis. Early Hum Dev 2009; 85: 187–189.
7.
Zanardo V, Vedovato S, Suppiej A, Trevisanuto D, Migliore M, Di Venosa B, Chiarelli S: Histological inflammatory responses in the placenta and early neonatal brain injury. Pediatr Dev Pathol 2008; 11: 350–354.
8.
Shobokshi A, Shaarawy M: Maternal serum and amniotic fluid cytokines in patients with preterm premature rupture of membranes with and without intrauterine infection. Int J Gynaecol Obstet 2002; 79: 209–215.
9.
Murtha AP, Sinclair T, Hauser ER, Swamy GK, Herbert WN, Heine RP: Maternal serum cytokines in preterm premature rupture of membranes. Obstet Gynecol 2007; 109: 121–127.
10.
Gulati S, Bhatnagar S, Raghunandan C, Bhattacharjee J: Interleukin-6 as a predictor of subclinical chorioamnionitis in preterm premature rupture of membranes. Am J Reprod Immunol 2012; 67: 235–240.
11.
Trochez-Martinez RD, Smith P, Lamont RF: Use of C-reactive protein as a predictor of chorioamnionitis in preterm prelabour rupture of membranes: a systematic review. BJOG 2007; 114: 796–801.
12.
Bek KM, Nielsen FR, Qvist I, Rasmussen PE, Tobiassen M: C-reactive protein (CRP) and pregnancy. An early indicator of chorioamnionitis. A review. Eur J Obstet Gynecol Reprod Biol 1990; 35: 29–33.
13.
Gulati S, Agrawal S, Raghunandan C, Bhattacharya J, Saili A, Agarwal S, Sharma D: Maternal serum interleukin-6 and its association with clinicopathological infectious morbidity in preterm premature rupture of membranes: a prospective cohort study. J Matern Fetal Neonatal Med 2012; 25: 1428–1432.
14.
Goldenberg RL, Hauth JC, Andrews WW: Intrauterine infection and preterm delivery. N Engl J Med 2000; 342: 1500–1507.
15.
Cobo T, Jacobsson B, Kacerovsky M, Hougaard DM, Skogstrand K, Gratacos E, Palacio M: Systemic and local inflammatory response in women with preterm prelabor rupture of membranes. PLoS One 2014; 9:e85277.
16.
Sorokin Y, Romero R, Mele L, Wapner RJ, Iams JD, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Harper M, Caritis SN, Miodovnik M, Mercer BM, Thorp JM, O’Sullivan MJ, Ramin SM, Carpenter MW, Rouse DJ, Sibai B: Maternal serum interleukin-6, C-reactive protein, and matrix metalloproteinase-9 concentrations as risk factors for preterm birth &#x3c; 32 weeks and adverse neonatal outcomes. Am J Perinatol 2010; 27: 631–640.
17.
Cobo T, Kacerovsky M, Palacio M, Hornychova H, Hougaard DM, Skogstrand K, Jacobsson B: A prediction model of histological chorioamnionitis and funisitis in preterm prelabor rupture of membranes: analyses of multiple proteins in the amniotic fluid. J Matern Fetal Neonatal Med 2012; 25: 1995–2001.
18.
Nergiz Avcioglu S, Demircan Sezer S, Kucuk M, Zafer E, Yuksel H, Akcan B, Turgut O: Maternal serum concentrations of s-Endoglin and IL-6 in pregnancy complicated by preterm premature membrane rupture. J Matern Fetal Neonatal Med 2016; 29: 1957–1962.
19.
Osanyin GE, Adegbola O: Maternal serum interleukin 6 levels and fetomaternal outcomes in women with preterm premature rupture of membranes in Lagos, South-western Nigeria. J Matern Fetal Neonatal Med 2016; 29: 3506–3510.
20.
Eleje GU, Ezugwu EC, Eke AC, Ikechebelu JI, Ezeama CO, Ezebialu IU, Ojiegbe NO, Obiora CC, Okafor CI, Udigwe GO, Nwosu BO, Ezugwu FO: Accuracy and response time of dual biomarker model of insulin-like growth factor binding protein-1/alpha fetoprotein (Amnioquick duo+) in comparison to placental alpha-microglobulin-1 test in diagnosis of premature rupture of membranes. J Obstet Gynaecol Res 2017; 43: 825–833.
21.
Jessop F, Sebire NJ: Histological chorioamnionitis: current concepts of diagnosis, classification and clinical significance. Fetal Matern Med Rev 2011; 22: 25–44.
22.
Tita AT, Andrews WW: Diagnosis and management of clinical chorioamnionitis. Clin Perinatol 2010; 37: 339–354.
23.
American College of Obstetricians and Gynecologists: ACOG Practice Bulletin No. 106: intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114: 192–202.
24.
DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837–845.
25.
Negishi H, Yamada H, Mikuni M, Kishida T, Okuyama K, Sagawa T, Makinoda S, Fujimoto S: Correlation between cytokine levels of amniotic fluid and histological chorioamnionitis in preterm delivery. J Perinat Med 1996; 24: 633–639.
26.
Baud O, Emilie D, Pelletier E, Lacaze-Masmonteil T, Zupan V, Fernandez H, Dehan M, Frydman R, Ville Y: Amniotic fluid concentrations of interleukin-1β, interleukin-6 and TNF-α in chorioamnionitis before 32 weeks of gestation: histological associations and neonatal outcome. Br J Obstet Gynaecol 1999; 106: 72–77.
27.
Kacerovsky M, Drahosova M, Hornychova H, Pliskova L, Bolehovska R, Forstl M, Tosner J, Andrys C: Value of amniotic fluid interleukin-8 for the prediction of histological chorioamnionitis in preterm premature rupture of membranes. Neuro Endocrinol Lett 2009; 30: 733–738.
28.
Yoneda S, Shiozaki A, Ito M, Yoneda N, Inada K, Yonezawa R, Kigawa M, Saito S: Accurate prediction of the stage of histological chorioamnionitis before delivery by amniotic fluid IL-8 level. Am J Reprod Immunol 2015; 73: 568–576.
29.
Shimoya K, Matsuzaki N, Taniguchi T, Okada T, Saji F, Murata Y: Interleukin-8 level in maternal serum as a marker for screening of histological chorioamnionitis at term. Int J Gynaecol Obstet 1997; 57: 153–159.
30.
Lee SM, Park JW, Kim BJ, Park CW, Park JS, Jun JK, Yoon BH: Acute histologic chorioamnionitis is a risk factor for adverse neonatal outcome in late preterm birth after preterm premature rupture of membranes. PLoS One 2013; 8:e79941.
31.
Aris IM, Logan S, Lim C, Choolani M, Biswas A, Bhattacharya S: Preterm prelabour rupture of membranes: a retrospective cohort study of association with adverse outcome in subsequent pregnancy. BJOG 2017; 124: 1698–1707.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.